#United States #Cranford #EVERSANA #LYMPHIR #Citius Oncology

Citius Oncology Enhances National Reach of LYMPHIR

Citius Oncology, Inc., a prominent player in biopharmaceuticals focused on oncology, has made significant strides in expanding the distribution of its innovative drug, LYMPHIR® (denileukin diftitox-cxdl). This development is part of a larger strategy to enhance physician engagement and improve patient outcomes, particularly for those suffering from relapsed or refractory cutaneous T-cell lymphoma (CTCL).

Expansion of Commercial Operations

As of July 2026, Citius Oncology has brought 21 new commercial field-based professionals on board, alongside eight dedicated medical science liaisons. The aim is to ensure that all personnel are fully operational by August 2026, thereby creating a robust presence across the United States. This expansion follows successful financing in May 2026 and is supported by EVERSANA, the exclusive commercialization partner for Citius Oncology. EVERSANA offers a comprehensive suite of services, which includes medical information, pharmacovigilance, revenue cycle management, and patient assistance.

Leonard Mazur, Chairman and CEO of Citius Oncology, expressed optimism about the project's progress, noting, "We believe we are on the verge of a significant growth phase for LYMPHIR with nearly complete access for payers and a growing number of treatment accounts beginning to place orders."

Physician Engagement and Adoption Trends

The integration of new team members comes at a critical time, as Citius Oncology has reported near-total payer coverage and noticeable growth in the number of physicians prescribing LYMPHIR. The feedback from healthcare professionals has been primarily positive, particularly regarding LYMPHIR's unique mechanism of action and its efficacy in treating CTCL.

Michael McGuire, Vice President of Commercial Operations, highlighted the importance of the newly implemented AI-driven commercial intelligence platform. This cutting-edge system supports enhanced customer engagement and streamlines resource allocation, effectively enabling teams to identify treatment opportunities more rapidly.

A Promising Future for LYMPHIR

LYMPHIR is meticulously designed to target relapsed or refractory CTCL, providing an innovative treatment option for patients who have undergone at least one prior systemic therapy. It operates as a recombinant fusion protein that combines the IL-2 receptor binding domain with fragments of diphtheria toxin, actively disrupting the proliferation of tumor cells.

The product has previously gained regulatory approval in Japan for similar indications and was launched in the U.S. in December 2025 following FDA approval. Current market estimates suggest that the initial market for LYMPHIR exceeds $400 million, indicating a high demand for innovative oncology treatments in this space.

Conclusion

As Citius Oncology continues to lay down substantial groundwork and improves its infrastructure and team, the potential for LYMPHIR stands strong. With increased physician awareness and effective outreach strategies, the company is poised for notable achievements in treating CTCL and advancing patient care in oncology. Citius remains committed to innovative solutions combined with high standards of patient safety and efficacy, promising a brighter future for those affected by CTCL.